Originally published by our sister publication Specialty Pharmacy Continuum
By Marcus A. Banks
Two studies presented at the 2024 meeting of the Immunoglobulin National Society (IgNS), in Washington, D.C., offer new insights into treatment options for immune globulin (IG) therapy.
Improving Primary Immunodeficiency
The first study outlined how an FDA-cleared immunoglobulin infusion set from Innovative Health Sciences aims to improve the experience of people with primary immunodeficiency (PI)